"Atacand Plus" monotherapy effective for new hypertensive patients.

Published: 2007-03-16 06:58:00

Updated: 2007-03-16 06:58:00

A study for 5,543 patients with high blood pressure in 5 major cities including Seoul, Busan, Daegu, Daejeon and Guangju who visited to private clinics reported that Atacand Plus, a combination anti-hypertension drug of an angiotensin receptor blocker and diuretics, showed an excellent hypotensiv...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK